MA53138A - Dérivés de 3-(5-hydroxy-1-oxoisoindoline-2-yl)pipéridine-2,6-dione et leur utilisation dans le traitement de maladies dépendantes du doigt de zinc 2 de la famille ikaros (ikzf2) - Google Patents
Dérivés de 3-(5-hydroxy-1-oxoisoindoline-2-yl)pipéridine-2,6-dione et leur utilisation dans le traitement de maladies dépendantes du doigt de zinc 2 de la famille ikaros (ikzf2)Info
- Publication number
- MA53138A MA53138A MA053138A MA53138A MA53138A MA 53138 A MA53138 A MA 53138A MA 053138 A MA053138 A MA 053138A MA 53138 A MA53138 A MA 53138A MA 53138 A MA53138 A MA 53138A
- Authority
- MA
- Morocco
- Prior art keywords
- ikzf2
- oxoisoindoline
- piperidine
- finger
- hydroxy
- Prior art date
Links
- JJUMFQGCQAUIFH-UHFFFAOYSA-N 3-(6-hydroxy-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione Chemical class C1C2=CC(O)=CC=C2C(=O)N1C1CCC(=O)NC1=O JJUMFQGCQAUIFH-UHFFFAOYSA-N 0.000 title 1
- 101000599037 Homo sapiens Zinc finger protein Helios Proteins 0.000 title 1
- 102000039995 Ikaros C2H2-type zinc-finger protein family Human genes 0.000 title 1
- 108091069197 Ikaros C2H2-type zinc-finger protein family Proteins 0.000 title 1
- 102100037796 Zinc finger protein Helios Human genes 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862695920P | 2018-07-10 | 2018-07-10 | |
| PCT/IB2019/055804 WO2020012334A1 (fr) | 2018-07-10 | 2019-07-08 | Dérivés de 3-(5-hydroxy-1-oxoisoindoline-2-yl)pipéridine-2,6-dione et leur utilisation dans le traitement de maladies dépendantes du doigt de zinc 2 de la famille ikaros (ikzf2) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA53138A true MA53138A (fr) | 2021-05-19 |
| MA53138B1 MA53138B1 (fr) | 2023-10-31 |
Family
ID=75905122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA53138A MA53138B1 (fr) | 2018-07-10 | 2019-07-08 | Dérivés de 3-(5-hydroxy-1-oxoisoindoline-2-yl)pipéridine-2,6-dione et leur utilisation dans le traitement de maladies dépendantes du doigt de zinc 2 de la famille ikaros (ikzf2) |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR116110A1 (fr) |
| MA (1) | MA53138B1 (fr) |
-
2019
- 2019-07-05 AR ARP190101914A patent/AR116110A1/es unknown
- 2019-07-08 MA MA53138A patent/MA53138B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA53138B1 (fr) | 2023-10-31 |
| AR116110A1 (es) | 2021-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL278951A (en) | History of 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-6,2-dione and their use in the treatment of IKZF2-dependent diseases | |
| MA51200A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA52003A (fr) | Procédés de traitement de maladies associées au hpv | |
| MA49458A (fr) | Composés interagissant avec la superfamille ras destinés à être utilisés dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques | |
| MA56392A (fr) | Dérivés de 2h-indazole et leur utilisation dans le traitement de maladies | |
| MA45550A (fr) | Dérivés de diazépinone et leur utilisation dans le traitement des infections par l'hépatite b | |
| MA50417A (fr) | Procédés d'utilisation d'inhibiteurs de l'ehmt2 dans le traitement ou la prévention de troubles du sang | |
| MA45089A (fr) | Utilisation d'indazoles 2-substitués pour le traitement et la prophylaxie de maladies auto-immunes | |
| MA50763A (fr) | Compositions d'acides aminés et méthodés de traitement de maladies et troubles musculaires | |
| MA51451A (fr) | Compositions d'acides aminés et méthodes de traitement de maladies hépatiques | |
| ATE478864T1 (de) | Hydantoinderivate zur behandlung von entzündlichen erkrankungen | |
| MA43980A (fr) | Méthodes de diagnostic et de pronostic de maladies et d'événements cardiovasculaires | |
| MA46585A (fr) | Méthodes de traitement de l'atrophie musculaire et des maladies osseuses faisant appel à de nouvelles protéines hybrides piégeant le ligand d'actriib | |
| BR112018011308A2 (pt) | anticorpos de peptídeo de beta amiloide anti-n3pglu e usos dos mesmos | |
| MA52873A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA47503A (fr) | Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales | |
| MA53127A (fr) | Utilisation de stimulateurs gcs pour le traitement de maladies mitochondriales | |
| MA56019A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA53614A (fr) | Protéine pour le traitement de maladies inflammatoires | |
| MA52631A (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
| MA54515A (fr) | Dérivés de quinoléine destinés à être utilisés dans le traitement de maladies inflammatoires | |
| MA44935A1 (fr) | Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4 , utilisée pour le traitement d"affections inflammatoires oculaires | |
| MA50905A (fr) | Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques | |
| MA54077A (fr) | Polythérapie pour le traitement de maladies hématologiques | |
| MA55143A (fr) | Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau |